VERASTEM INC(NASDAQ:VSTM) stock News

VSTM Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Zacks Investment Research

Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice

2 days ago - By: Zacks Investment Research

Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet

4 days ago - By: Verastem Oncology

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

15 days ago - By: Verastem Oncology

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

2 months ago - By: Verastem Oncology

Verastem Oncology to Present at Upcoming Investor Conferences

2 months ago - By: Yahoo Finance

Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects

2 months ago - By: Benzinga - Mentions: CDXS PULM SNOA OVID ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

2 months ago - By: Verastem Oncology

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

3 months ago - By: Zacks Investment Research - Mentions: KMDA

Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates

3 months ago - By: Verastem Oncology

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

3 months ago - By: Zacks Investment Research - Mentions: GOSS

Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates

3 months ago - By: Verastem Oncology

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

3 months ago - By: Verastem Oncology

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

3 months ago - By: Verastem Oncology

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

4 months ago - By: FN Media Group LLC - Mentions: ONCY ONC.CA MBIO CRDF ...

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

4 months ago - By: Verastem Oncology

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Verastem Oncology

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

4 months ago - By: Verastem Oncology

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

4 months ago - By: Zacks Investment Research - Mentions: EXAS GH TEM

Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?

5 months ago - By: Stocktwits - Mentions: VTI IWM

Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish

5 months ago - By: Verastem Oncology

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

5 months ago - By: Zacks Investment Research - Mentions: LXRX AMRN

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval

5 months ago - By: Verastem Oncology

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

5 months ago - By: Verastem Oncology

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

5 months ago - By: Yahoo Finance - Mentions: DB GOOG RBLX HD ...

Deutsche Bank Reaffirms Buy Rating on Roblox Amid Google Deal

5 months ago - By: Verastem Oncology

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

6 months ago - By: Stocktwits - Mentions: VTI IWM

VERASTEM INC (VSTM) Stock News

VSTM Latest News, Press Relases and Analysis

Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice

Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Earnings Scheduled For August 7, 2025

Verastem Oncology to Present at Upcoming Investor Conferences

Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects

12 Health Care Stocks Moving In Wednesday's After-Market Session

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?

Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

Deutsche Bank Reaffirms Buy Rating on Roblox Amid Google Deal

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased